Increasing CD200R-mediated signaling constitutes a potential approach to manage monocyte- and Th2-mediated autoimmune disorders, which could lead not only to a short-term impact on disease but potentially also to disease modification and hence durability of response posttreatment19. The gene discussed is CD200R1; the disease is autoimmune disease.